F
F. Al Hosani
Publications - 7
Citations - 605
F. Al Hosani is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 2 publications receiving 526 citations.
Papers
More filters
Journal ArticleDOI
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.
A. Sibley,Kwang Hyub Han,A. Abourached,Laurentius A. Lesmana,Mihály Makara,Wasim Jafri,Riina Salupere,Abdullah M. Assiri,Adrian Goldis,Faisal Abaalkhail,Zaigham Abbas,A. Abdou,F. Al Braiki,F. Al Hosani,K. Al Jaberi,M. Al Khatry,M. A. Al Mulla,H. Al Quraishi,A. Al Rifai,Y. Al Serkal,Altaf Alam,Seyed Moayed Alavian,Hamad I. Al-Ashgar,S. Alawadhi,L. Al-Dabal,P. Aldins,Faleh Z. Al-Faleh,Abdullah S. Alghamdi,R. Al-Hakeem,Abdulrahman Aljumah,A. Almessabi,Adel Alqutub,Khalid Alswat,Ibrahim Altraif,M. Alzaabi,N. Andrea,Mohamed A. Babatin,A. Baqir,M. T. Barakat,Ottar M. Bergmann,Abdul Rahman Bizri,Sarah Blach,Asad Chaudhry,M. S. Choi,T. Diab,Samsuridjal Djauzi,E. S. El Hassan,S. El Khoury,Chris Estes,S. Fakhry,J. I. Farooqi,J. I. Farooqi,H. Fridjonsdottir,Rino Alvani Gani,A. Ghafoor Khan,Liana Gheorghe,Magnus Gottfredsson,S. Gregorcic,Jessie Gunter,Behzad Hajarizadeh,Behzad Hajarizadeh,Saeed Hamid,Irsan Hasan,Almoutaz Hashim,Gabor Horvath,Béla Hunyady,R. Husni,Agita Jeruma,Jon G. Jonasson,Jon G. Jonasson,B. Karlsdottir,Do Young Kim,Young Seok Kim,Z. Koutoubi,Valentina Liakina,Valentina Liakina,Young-Suk Lim,A. Löve,A. Löve,Matti Maimets,Reza Malekzadeh,Mojca Maticic,Muhammad S. Memon,Shahin Merat,Jacques E Mokhbat,Fadi H. Mourad,David H. Muljono,David H. Muljono,Arif Nawaz,N. Nugrahini,S. Olafsson,S. Priohutomo,H. Qureshi,P. Rassam,Homie Razavi,Devin Razavi-Shearer,Kathryn Razavi-Shearer,Baiba Rozentale,M. Sadik,K. Saeed,A. Salamat,Faisal M. Sanai,A. Sanityoso Sulaiman,R. A. Sayegh,Ala I. Sharara,M. Siddiq,A. M. Siddiqui,G. Sigmundsdottir,B. Sigurdardottir,Danute Speiciene,Andri Sanityoso Sulaiman,Marwa Sultan,M. Taha,Junko Tanaka,H. Tarifi,G. Tayyab,Ieva Tolmane,M. Ud Din,M. Umar,M. Umar,M. Umar,Jonas Valantinas,J. Videčnik-Zorman,Cesar Yaghi,Evy Yunihastuti,M. A. Yusuf,Bader Faiyaz Zuberi,Jonathan Schmelzer +127 more
TL;DR: The current treatment rate and efficacy are not sufficient to manage the disease burden of hepatitis C virus and alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver‐related deaths from increasing.
Journal ArticleDOI
Strategies to manage hepatitis C virus infection disease burden - Volume 3
Faleh Z. Al-Faleh,N. Nugrahini,Mojca Matičič,Ieva Tolmane,M. Alzaabi,Behzad Hajarizadeh,Behzad Hajarizadeh,Jonas Valantinas,Do Young Kim,Béla Hunyady,Faisal Abaalkhail,Zaigham Abbas,A. Abdou,A. Abourached,F. Al Braiki,F. Al Hosani,K. Al Jaberi,M. Al Khatry,M. A. Al Mulla,H. Al Quraishi,A. Al Rifai,Y. Al Serkal,Altaf Alam,Hamad I. Al-Ashgar,Seyed M Alavian,S. Alawadhi,L. Al-Dabal,P. Aldins,Abdullah S. Alghamdi,R. Al-Hakeem,Abdulrahman Aljumah,A. Almessabi,Adel Alqutub,Khalid Alswat,Ibrahim Altraif,N. Andrea,Abdullah M. Assiri,Mohamed A. Babatin,A. Baqir,M. T. Barakat,Ottar M. Bergmann,Abdul Rahman Bizri,Asad Chaudhry,Moon Suk Choi,T. Diab,Samsuridjal Djauzi,E. S. El Hassan,S. El Khoury,Chris Estes,S. Fakhry,Javed Iqbal Farooqi,Javed Iqbal Farooqi,H. Fridjonsdottir,Rino Alvani Gani,A. Ghafoor Khan,Liana Gheorghe,Adrian Goldis,Magnus Gottfredsson,S. Gregorcic,Jessie Gunter,Saeed Hamid,Kwang Hyub Han,Irsan Hasan,Almoutaz Hashim,Gabor Horvath,R. Husni,Wasim Jafri,Agita Jeruma,Jon G. Jonasson,Jon G. Jonasson,B. Karlsdottir,Young Seok Kim,Z. Koutoubi,Laurentius A. Lesmana,Valentina Liakina,Valentina Liakina,Young-Suk Lim,A. Löve,A. Löve,Matti Maimets,Mihály Makara,Reza Malekzadeh,Muhammad S. Memon,Shahin Merat,Jacques E Mokhbat,Fadi H. Mourad,David H. Muljono,David H. Muljono,Arif Nawaz,S. Olafsson,S. Priohutomo,H. Qureshi,P. Rassam,Homie Razavi,Devin Razavi-Shearer,Kathryn Razavi-Shearer,Baiba Rozentale,M. Sadik,K. Saeed,A. Salamat,Riina Salupere,Faisal M. Sanai,A. Sanityoso Sulaiman,R. A. Sayegh,Jonathan Schmelzer,Ala I. Sharara,A. Sibley,M. Siddiq,A. M. Siddiqui,G. Sigmundsdottir,B. Sigurdardottir,Danute Speiciene,Andri Sanityoso Sulaiman,Marwa Sultan,M. Taha,Junko Tanaka,H. Tarifi,G. Tayyab,M. Ud Din,M. Umar,M. Umar,J. Videčnik-Zorman,Cesar Yaghi,Evy Yunihastuti,M. A. Yusuf,Bader Faiyaz Zuberi,Sarah Blach +126 more
TL;DR: A 90% reduction in total HCV infections within 15 years is feasible in most countries studied, but it required a coordinated effort to introduce harm reduction programmes to reduce new infections, screening to identify those already infected and treatment with high cure rate therapies.
Journal ArticleDOI
Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates
Nawal Al Kaabi,Abderrahim Oulhaj,Subhashini Ganesan,F. Al Hosani,Omer Najim,Halah Ibrahim,Juan Alexis Acuña,Ahmed R. Alsuwaidi,Ashraf Kamour,Ashraf Alzaabi,B. Al Shehhi,Habiba Al Safar,Salah Eldin Hussein,J. Abdalla,Dalal Saeed Naser Al Mansoori,Ahmed Al hammadi,Mohammed Amari,Ahmed Al Romaithi,Stefan Weber,Santosh Elavalli,I. Eltantawy,N. Alghaithi,Jumana Al Azazi,Stephen G Holt,Mohamed Mostafa,Rabih Halwani,Hanif Khalak,Wael Mohamed Elamin,Rami Beiram,Walid Abbas Zaher +29 more
TL;DR: The effectiveness of the inactivated BBIBP-CorV vaccine against severe COVID-19 outcomes (hospitalization, critical care admission and death due to COVID19) and its long-term effectiveness have not been well characterized among the general population as mentioned in this paper .
Journal ArticleDOI
The integration of mHealth technologies in telemedicine during the COVID-19 era: A cross-sectional study
Abdul Rahman Taha,Mustafa Shehadeh,Ali S. Alshehhi,Tariq R. Altamimi,E. Housser,M. C. Emre Simsekler,Buthaina Alfalasi,Shamma Abdullah Al Memari,F. Al Hosani,Yousif Al Zaabi,Shereen Almazroui,Hamed Alhashemi,Noora Alhajri +12 more
TL;DR: The study results support that the use of mHealth applications is associated with increased patient satisfaction with telemedicine appointments, and this study was a survey-based study that included outpatients from Abu Dhabi.
Journal ArticleDOI
The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates
Nawal Al Kaabi,Abderrahim Oulhaj,F. Al Hosani,Shamma Al Mazrouei,Omer Najim,Salah Eldin Hussein,J. Abdalla,M. Fasihuddin,Afnan Abdellatif Hassan,Gehad ElGhazali,Ahmed Al Rumaithi,Jumana Al Azazi,Stefan Weber,Rami Beiram,Khatija A. Parekh,Mohamud Sheek-Hussein,Yunkai Yang,Yang Xiaoming,Jenny Quliang,I. Eltantawy,S. Mahmoud,A. Koshy,P. Xiao,Subhashini Ganesan,Wael Mohamed Elamin,Walid Abbas Zaher +25 more
TL;DR: A prospective cohort study was conducted among frontline workers to estimate the incidence rate and risk of symptomatic COVID-19 infection 14 days after the second dose of inoculation with BBIBP-CORV inactivated vaccine as discussed by the authors .